Combination therapy is the cornerstone of modern oncology. By targeting multiple pathways simultaneously, researchers hope to overcome drug resistance, reduce toxicity through dose sparing, and achieve synergistic tumor cell killing.
But how do you rationally design combination screens involving FAK (PTK2) ? And why is a PTK2 knockout cell line a superior tool compared to FAK inhibitors when screening for synergistic drug combinations?
This blog post provides a practical, data-driven guide to using the AhelixBio PTK2 Knockout A549 Cell Line (YKO-HS1818) in drug combination screens.
FAK is an attractive combination target for several reasons:
| Reason | Explanation |
|---|---|
| FAK is hyperactivated in NSCLC | High FAK expression correlates with poor prognosis and chemoresistance in lung adenocarcinoma |
| FAK mediates resistance to multiple therapies | Evidence shows FAK activation contributes to resistance against chemotherapy, targeted therapy, and immunotherapy |
| FAK inhibition is well-tolerated | Clinical-stage FAK inhibitors (defactinib, GSK2256098) have shown manageable toxicity profiles |
| FAK knockout sensitizes to multiple drugs | Published data indicate PTK2 KO A549 cells show enhanced sensitivity to cisplatin, paclitaxel, and EGFR inhibitors |
The Key Insight: FAK is not usually a "driver" oncogene in NSCLC. Instead, it is a survival and escape pathway that becomes activated when cancer cells are stressed by drugs. Knocking out PTK2 removes this escape route.
| Feature | PTK2 KO (AhelixBio A549-PTK2KO) | FAK Inhibitor (e.g., Defactinib) |
|---|---|---|
| FAK status during screen | Completely absent (100% loss) | Inhibited only when drug is present |
| Can cells recover? | No (permanent) | Yes (inhibitor washes out) |
| Scaffolding functions blocked? | Yes | No |
| Controls for off-target effects | Compare WT vs. KO | Add inhibitor to KO cells as control |
| Throughput | High (pre-plate KO cells across plates) | High (add inhibitor via liquid handler) |
| Cost for 384-well screen | Low (no compound needed for KO baseline) | Moderate (inhibitor cost adds up) |
The Bottom Line: Using a PTK2 knockout line provides a clean genetic baseline for identifying drugs that rely on FAK for resistance. If a drug works equally well in WT and KO cells, FAK is not involved in resistance. If the drug works better in KO cells, FAK is a resistance mechanism.
| Strategy | Description | Best For |
|---|---|---|
| Sensitization screen | Test drug library on WT vs. KO cells; identify drugs with enhanced efficacy in KO | Finding drugs that overcome FAK-mediated resistance |
| Combination matrix | Titrate FAK inhibitor + test drug in WT cells; compare to KO baseline | Validating synergy and finding optimal ratios |
| Rescue screen | Add back FAK (via overexpression) to KO cells; test if resistance returns | Confirming on-target effects |
| Plate Type | Cells per Well (WT A549) | Cells per Well (PTK2 KO) | Notes |
|---|---|---|---|
| 96-well | 5,000–10,000 | 5,000–10,000 | KO may grow slower; seed same number |
| 384-well | 1,000–2,500 | 1,000–2,500 | Use multichannel or automated dispenser |
| 1536-well | 250–500 | 250–500 | High-throughput; requires automation |
Critical Note: PTK2 KO A549 cells often have a reduced proliferation rate. Always perform a growth curve comparison before screening to ensure equal cell numbers at the time of drug addition. Adjust seeding density if needed.
Recommended Dilution Scheme for Combination Matrices:
| Drug A (Test Compound) Concentration | Drug B (FAK Inhibitor or Control) Concentration |
|---|---|
| 8-point serial dilution (e.g., 10 µM to 0.001 µM) | 8-point serial dilution (e.g., 10 µM to 0.001 µM) |
| Full 8×8 matrix = 64 unique combinations | Include single-agent controls for both drugs |
Control Conditions (Essential):
| Control | Cell Line | Purpose |
|---|---|---|
| Untreated | WT A549 | Baseline viability |
| Untreated | PTK2 KO A549 | Baseline viability (may be lower) |
| Vehicle (DMSO) | Both | Control for solvent effects |
| Single agent (drug alone) | Both | Establish single-agent dose-response |
| Combination | Both | Test synergy |
| FAK inhibitor alone | Both | Benchmark for FAK targeting |
| Assay | Mechanism | Best For | Compatibility with KO |
|---|---|---|---|
| CellTiter-Glo (ATP) | Luciferase-based ATP detection | High-throughput screens | Excellent |
| CCK-8 | WST-8 reduction by dehydrogenases | Standard 96-well assays | Excellent (KO cells are metabolically active) |
| SRB (Sulforhodamine B) | Protein content staining | Long-term (72h+) assays | Good (KO cells have less protein? Normalize carefully) |
| Resazurin (Alamar Blue) | Fluorescent reduction | Live-cell kinetic assays | Good |
| MTS / MTT | Tetrazolium reduction | Standard assays | Acceptable (slow-growing KO may show lower signal) |
Recommendation: Use CellTiter-Glo for highest sensitivity and throughput. For PTK2 KO cells, the signal-to-background ratio remains excellent.
| Method | Formula / Approach | Best For |
|---|---|---|
| Bliss Independence | Expected effect = Effect_A + Effect_B – (Effect_A × Effect_B) | Additive drugs; most common |
| Loewe Additivity | Uses dose-response curves; requires curve fitting | Drugs with similar mechanisms |
| Highest Single Agent (HSA) | Synergy if combination > max(Effect_A, Effect_B) | Conservative estimate |
| ZIP (Zero Interaction Potency) | Combines Bliss and Loewe; newer method | Most robust for screening |
Software Options:
| Software | Cost | Features |
|---|---|---|
| SynergyFinder | Free (web-based) | ZIP, Bliss, Loewe, HSA; generates synergy heatmaps |
| Combenefit | Free | Visualizes synergy landscapes |
| Chou-Talalay (CompuSyn) | Paid (Legacy) | Combination Index (CI) values |
| GraphPad Prism | Paid | Combination matrices with synergy heatmaps (newer versions) |
Scenario 1: Drug shows enhanced efficacy in PTK2 KO vs. WT
| Observation | Interpretation |
|---|---|
| IC50 is 3–10× lower in KO cells | FAK is a resistance mechanism for this drug |
| Max kill is higher in KO cells | FAK protects cells from death even at high doses |
| Combination of drug + FAK inhibitor phenocopies KO | FAK inhibition is sufficient; scaffolding not required |
Scenario 2: Drug shows same efficacy in WT and KO
| Observation | Interpretation |
|---|---|
| IC50 is identical | FAK is not involved in resistance to this drug |
| KO does not sensitize | Focus combination efforts elsewhere |
Scenario 3: Drug shows less efficacy in KO (rare)
| Observation | Interpretation |
|---|---|
| KO cells are resistant to drug | FAK loss may activate compensatory pathways (e.g., PTK2B/PYK2) |
| Check PTK2B expression | Consider dual FAK/PYK2 targeting |
Based on data from the literature (representative findings):
| Drug Class | Example Drug | Effect of PTK2 Knockout in A549 |
|---|---|---|
| Platinum-based chemo | Cisplatin | 3–5× enhanced sensitivity |
| Taxanes | Paclitaxel | Moderate sensitization (2×) |
| Anti-metabolites | Gemcitabine | Mild to moderate sensitization |
| EGFR inhibitors | Osimertinib, Gefitinib | Enhanced sensitivity (A549 is KRAS mutant, so EGFRi alone is weak; FAK KO improves response) |
| MEK inhibitors | Trametinib | Synergistic effect observed |
| PARP inhibitors | Olaparib | Minimal sensitization (A549 is HR-proficient) |
Takeaway: The strongest sensitization effects are seen with DNA-damaging agents (cisplatin) and EGFR pathway inhibitors.
After identifying candidate combinations in your primary screen, validate with this orthogonal approach:
| Step | Validation Method | Purpose | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Repeat 8×8 matrix in triplicate | Confirm synergy score | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | Colony formation assay (14 days) | Long-term survival effect | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | Apoptosis assay (Caspase-3/7 or Annexin V) | Mechanism of enhanced killing | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | Western blot for pathway markers | Confirm target engagement (p-FAK, p-AKT, p-ERK) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 | Test in PTK2 KO + FAK re-expression | Confirm on-target effect (rescue experiment)
Controls You Cannot Skip
Troubleshooting Common Issues
Frequently Asked QuestionsQ: Can I use PTK2 KO A549 cells to screen for drugs that specifically kill FAK-dependent cancers? A: Yes. This is a classic "synthetic lethal" screen. Compare WT vs. KO viability across a drug library. Drugs that kill WT but not KO are "FAK-dependent toxic" (less common). Drugs that kill KO better than WT are "overcoming FAK-mediated resistance" (more common). Q: How many replicates do I need for a reliable synergy score? A: For publication-quality data: 3 biological replicates (separate passages) × 2 technical replicates per plate = 6 total replicates per condition. Q: What is a good synergy score? A: Using SynergyFinder's ZIP method:
Q: Should I include a FAK inhibitor in the screen if I already have a KO line? A: Yes. Including a FAK inhibitor (e.g., defactinib, PF-562,271) alongside your test compounds allows you to distinguish between:
Q: Can I use this cell line for in vivo combination studies? A: Absolutely. PTK2 KO A549 cells form tumors in NSG or nude mice. Compare WT vs. KO tumors treated with your drug of interest. If the drug works better in KO tumors, FAK is a resistance mechanism in vivo. Summary: Key Takeaways for Drug Screens
|
